REG - Arecor Therapeutics - Notice of Interim Results

Arecor TherapeuticsAnnouncement

03/09/2021 07:05

RNS Number : 5963K
  
Arecor Therapeutics PLC
  
03 September 2021
  
 

Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
 
NOTICE OF INTERIM RESULTS
 
Cambridge, UK, 3 September 2021: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical group advancing today's therapies to enable healthier lives, will announce its maiden Interim Results for the six months ended 30 June 2021 on Thursday 23 September 2021. 
 
Sarah Howell, Chief Executive Officer, and Susan Lowther, Chief Financial Officer, will host a virtual briefing for analysts and investors at 11:00 AM on the day of the results. 
 
 For more details or to attend the virtual briefing, please contact arecor@consilium-comms.com
 
 
-ENDS-
 
For more information, please contact: 



Arecor Therapeutics plc


www.arecor.com






Dr Sarah Howell, Chief Executive Officer


Tel: +44 (0) 1223 426060
Email: info@arecor.com














Susan Lowther, Chief Financial Officer


Tel: +44 (0) 1223 426060
Email: info@arecor.com














Mo Noonan, Communications


Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com














Panmure Gordon (UK) Limited (NOMAD and Broker) 








Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)


Tel: +44 (0) 20 7886 2500
 














Consilium Strategic Communications








Chris Gardner, David Daley, Angela Gray


Tel: +44 (0) 20 3709 5700
Email: arecor@consilium-comms.com 





Notes to Editors
 
About Arecor 
Arecor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.
 
For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NORBUGDCSDGDGBD